# Efficacy and Safety of DLBS2411 in the Management of GERD

> **NCT03367195** · PHASE3 · TERMINATED · sponsor: **Dexa Medica Group** · enrollment: 32 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** Omeprazole
- **DRUG:** DLBS2411
- **DRUG:** Placebo capsule of Omeprazole
- **DRUG:** Placebo caplet of DLBS2411

## Key facts

- **NCT ID:** NCT03367195
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-16
- **Primary completion:** 2020-05-04
- **Final completion:** 2020-09-09
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Very low recruitment rate. The Study Site classifies as tertiary referral hospital. Therefore, GERD Patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367195, "Efficacy and Safety of DLBS2411 in the Management of GERD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03367195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*